KILITCH

Kilitch Drugs(I) Share Price

₹390.00 -12.65 (-3.14%)

02 May, 2025 22:46

SIP TrendupStart SIP in KILITCH

Start SIP

Performance

  • Low
  • ₹385
  • High
  • ₹425
  • 52 Week Low
  • ₹300
  • 52 Week High
  • ₹431
  • Open Price₹401
  • Previous Close₹403
  • Volume86,924

Investment Returns

  • Over 1 Month + 8.32%
  • Over 3 Month + 24.28%
  • Over 6 Month + 21.25%
  • Over 1 Year + 7.53%
SIP Lightning

Smart Investing Starts Here Start SIP with Kilitch Drugs(I) for Steady Growth!

Invest Now

Kilitch Drugs(I) Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 32.1
  • PEG Ratio
  • 0.9
  • Market Cap Cr
  • 627
  • P/B Ratio
  • 3.3
  • Average True Range
  • 25.32
  • EPS
  • 12.13
  • Dividend Yield
  • 0
  • MACD Signal
  • 7.98
  • RSI
  • 65.86
  • MFI
  • 84.65

Kilitch Drugs(I) Financials

Kilitch Drugs(I) Technicals

EMA & SMA

Current Price
₹390.00
-12.65 (-3.14%)
pointer
  • stock-down_img
  • Bearish Moving Average 0
  • stock-up_img
  • Bullish Moving Average 16
  • 20 Day
  • ₹359.32
  • 50 Day
  • ₹344.64
  • 100 Day
  • ₹337.38
  • 200 Day
  • ₹333.77

Resistance and Support

400.07 Pivot Speed
  • R3 455.33
  • R2 440.27
  • R1 415.13
  • S1 374.93
  • S2 359.87
  • S3 334.73

What's your outlook on Kilitch Drugs(I)?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Kilitch Drugs India has an operating revenue of Rs. 181.91 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 13% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 19% and 20% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 97 which is a GREAT score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Overall, the stock has great fundamentals and technical strength to stay in momentum.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Kilitch Drugs(I) Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-11 Quarterly Results
2024-11-12 Quarterly Results
2024-08-08 Quarterly Results
2024-05-27 Quarterly Results
2024-02-08 Quarterly Results

Kilitch Drugs(I) F&O

Kilitch Drugs(I) Shareholding Pattern

69.23%
0%
0%
25.57%
5.2%

About Kilitch Drugs(I)

  • NSE Symbol
  • KILITCH
  • BSE Symbol
  • 524500
  • Managing Director
  • Mr. Mukund P Mehta
  • ISIN
  • INE729D01010

Similar Stocks to Kilitch Drugs(I)

Kilitch Drugs(I) FAQs

Kilitch Drugs(I) share price is ₹390 As on 02 May, 2025 | 22:32

The Market Cap of Kilitch Drugs(I) is ₹627.2 Cr As on 02 May, 2025 | 22:32

The P/E ratio of Kilitch Drugs(I) is 32.1 As on 02 May, 2025 | 22:32

The PB ratio of Kilitch Drugs(I) is 3.3 As on 02 May, 2025 | 22:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23